SMO Clinplus Co (SZSE:301257) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co Debt-to-Equity?

SMO Clinplus Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥5.9 Mil. SMO Clinplus Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥3.2 Mil. SMO Clinplus Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,106.2 Mil. SMO Clinplus Co's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SMO Clinplus Co's Debt-to-Equity or its related term are showing as below:

SZSE:301257' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.03
Current: 0.01

During the past 7 years, the highest Debt-to-Equity Ratio of SMO Clinplus Co was 0.03. The lowest was 0.00. And the median was 0.01.

SZSE:301257's Debt-to-Equity is ranked better than
99.48% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs SZSE:301257: 0.01

SMO Clinplus Co Debt-to-Equity Historical Data

The historical data trend for SMO Clinplus Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co Debt-to-Equity Chart

SMO Clinplus Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.01

SMO Clinplus Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of SMO Clinplus Co's Debt-to-Equity

For the Diagnostics & Research subindustry, SMO Clinplus Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SMO Clinplus Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's Debt-to-Equity falls into.

SMO Clinplus Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SMO Clinplus Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.606	+	5.476)	/	1080.595
	=	0.01

SMO Clinplus Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.856	+	3.229)	/	1106.217
	=	0.01

SMO Clinplus Co (SZSE:301257) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SMO Clinplus Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SMO Clinplus Co (SZSE:301257) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001

Website

http://www.smo-clinplus.com

SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.

Executives

Lai Chun Bao	Director
Ma Lin	Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines